Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$43.73 USD

43.73
614,131

+0.56 (1.30%)

Updated May 24, 2024 04:00 PM ET

After-Market: $43.75 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Qiagen (QGEN) Up 9.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

by Zacks Equity Research

QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

by Zacks Equity Research

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

by Zacks Equity Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

by Zacks Equity Research

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down

by Zacks Equity Research

In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.

Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 2.04% and 0.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Techne (TECH) Q1 Earnings Expected to Decline

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

by Zacks Equity Research

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

Charles River (CRL) Launches LVV-based Gene Therapy Platform

by Zacks Equity Research

Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.

QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software

by Zacks Equity Research

QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

by Zacks Equity Research

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

QIAGEN's (QGEN) New API Streamlines Access to BKB Data

by Zacks Equity Research

QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.

Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed

by Zacks Equity Research

QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.

Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 2% and 0.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test

by Zacks Equity Research

QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.

Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?

by Zacks Equity Research

Emergent Biosolutions (EBS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

QIAGEN (QGEN) Expands Digital PCR Offering With New Pact

by Zacks Equity Research

QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.

Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.